Stifel lowered the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$17 from C$19 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions
- Cipher Pharmaceuticals’ Revenue Soars After Natroba Acquisition
- CPHRF Earnings this Week: How Will it Perform?
- Cipher Pharmaceuticals Announces Q3 2024 Financial Results
- Cipher Pharmaceuticals price target raised to C$19 from C$17 at Stifel